Difference between revisions of "Cladribine (Leustatin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(44 intermediate revisions by 5 users not shown)
Line 1: Line 1:
−
Also known as 2-chlorodeoxyadenosine, 2-CdA.
+
==General information==
 +
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe Cladribine package insert]</ref><ref>[[:File:Cladribine.pdf | Cladribine (Leustatin) package insert (locally hosted backup)]]</ref>
 +
<br>Route: IV, SC
 +
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference
  
−
==General information==
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>  
−
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.<ref name="insert">[http://www.janssenbiotech.com/assets/Leustatin_PI.pdf Cladribine (Leustatin)) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/cladribine.pdf Cladribine (Leustatin) package insert (locally hosted backup)]</ref>
+
==Diseases for which it is established ''(work in progress)''==
−
<br>Route: IV
+
*[[Mantle cell lymphoma]]
−
<br>Extravasation: [[irritant]]
 
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.
+
==Diseases for which it is used==
 +
*[[Acute myeloid leukemia]]
 +
*[[B-cell lymphoma of mucosa-associated lymphoid tissue]]
 +
*[[Chronic lymphocytic leukemia]]
 +
*[[Follicular lymphoma]]
 +
*[[Hairy cell leukemia]]
 +
*[[Hypereosinophilic syndrome]]
 +
*[[Langerhans cell histiocytosis]]
 +
*[[Systemic mastocytosis]]
 +
*[[Waldenström macroglobulinemia]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/bio/cladribine.asp Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/cladribine.asp Cladribine (Leustatin) patient drug information (Chemocare)]</ref>
+
*[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe Cladribine package insert]<ref name="insert"></ref>
 +
*[https://chemocare.com/druginfo/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
* 1993-02-26: Initial FDA approval for treatment of active [[hairy cell leukemia]]. ''(Based on Saven et al. 1998)''
 +
==History of changes in EMA indication==
 +
*1993-02-26: EURD
 +
==Also known as==
 +
*'''Generic names:''' 2-chlorodeoxyadenosine, 2-CdA
 +
*'''Brand names:''' Leustatin, Litak, Movectro
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
 +
[[Category:Subcutaneous medications]]
 +
[[Category:Irritant]]
 +
[[Category:Neutral]]
 +
 +
[[Category:Antimetabolites]]
 +
[[Category:Purine analogs]]
 +
 +
[[Category:Acute myeloid leukemia medications]]
 +
[[Category:Chronic lymphocytic leukemia medications]]
 +
[[Category:Follicular lymphoma medications]]
 +
[[Category:Hairy cell leukemia medications]]
 +
[[Category:Hypereosinophilic syndrome medications]]
 +
[[Category:Langerhans cell histiocytosis medications]]
 +
[[Category:MALT lymphoma medications]]
 +
[[Category:Mantle cell lymphoma medications]]
 +
[[Category:Systemic mastocytosis medications]]
 +
[[Category:Waldenström macroglobulinemia medications]]
 +
 +
[[Category:FDA approved in 1993]]
 +
[[Category:EMA approved in 1993]]

Latest revision as of 01:02, 29 June 2024

General information

Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV, SC
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1993-02-26: Initial FDA approval for treatment of active hairy cell leukemia. (Based on Saven et al. 1998)

History of changes in EMA indication

  • 1993-02-26: EURD

Also known as

  • Generic names: 2-chlorodeoxyadenosine, 2-CdA
  • Brand names: Leustatin, Litak, Movectro

References

  1. ↑ 1.0 1.1 1.2 Cladribine package insert
  2. ↑ Cladribine (Leustatin) package insert (locally hosted backup)
  3. ↑ Cladribine (Leustatin) patient drug information (Chemocare)
  4. ↑ Cladribine (Leustatin) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Cladribine_(Leustatin)&oldid=87306"